The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...

On BeiGene’s very first live earnings call, CEO and co-founder John Oyler on Thursday described a “once-in-a-lifetime ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively. Check out why I rate ONC stock as a Buy.

BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...

BofA analyst David Li upgraded BeiGene (ONC) to Buy from Neutral with a price target of $320, up from $207. The firm raised its revenue ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...

BeiGene (ONC) announced the U.S. FDA has approved Ttevimbra in combination with platinum-containing chemotherapy, for the first-line treatment ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...